In conclusion, this study describes the use of a novel VEGFR2 antagonist peptoid, GU81, to effectively control tumor growth in combination with doxorubicin in a transgenic model of breast cancer that closely mimics human disease progression. The gene discussed is KDR; the disease is breast carcinoma.